Ontology highlight
ABSTRACT: Background
New targeted antibody-drug conjugates (ADCs) against multiple myeloma are known to induce adverse effects that may lead to treatment discontinuation. Preclinical studies reported early severe ocular damage related to the use of belantamab mafodotin (belamaf), including ocular surface inflammation, severe dry eye, and a specific toxicity to the cornea, namely microcystic keratopathy. While belamaf-induced ocular changes have not been prospectively studied, a better understanding of mechanisms involved as well as kinetics may aid in anticipating dose adjustment rather than stopping the treatment once clinical ocular damage is too severe.Case presentation
A 61-year-old woman scheduled for belamaf as a fifth-line treatment against multiple myeloma was prospectively i
SUBMITTER: Marquant K
PROVIDER: S-EPMC8489063 | biostudies-literature | 2021 Oct
REPOSITORIES: biostudies-literature